---
document_datetime: 2023-09-21 21:58:25
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_en.pdf
document_name: pombiliti-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.814066
conversion_datetime: 2025-12-30 08:45:38.277252
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form                              | Route of administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|--------------------------------------------------|---------------------------|-----------------------|-------------|
| EU/1/22/1714/001 | Pombiliti         | 105 mg     | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 vial      |
| EU/1/22/1714/002 | Pombiliti         | 105 mg     | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 vials    |
| EU/1/22/1714/003 | Pombiliti         | 105 mg     | Powder for concentrate for solution for infusion | Intravenous use           | vial (glass)          | 25 vials    |

<div style=\"page-break-after: always\"></div>

## NOTE:

## This is a sample English Annex A template only.

The English Annex A template is not provided as it is prepared by the European Medicines Agency. Translations of Annex A must be in line and consistent with the adopted English product information annexes of the product concerned.